Xeris Biopharma Reaches License Agreement With Amgen On Thyroid Eye Disease Treatment
10 Janeiro 2024 - 10:53AM
Dow Jones News
By Ben Glickman
Xeris Biopharma has entered an exclusive worldwide license
agreement with Amgen related to a subcutaneous formulation of a
Thyroid Eye Disease treatment.
The Chicago-based biopharmaceutical company said Amgen would
develop, manufacture and commercialize the formulation of
teprotumumab using Xeris' XeriJect technology.
Xeris may receive up to $75 million based on development and
regulatory milestones in addition to sales milestones. The company
will also get royalties on future sales of Tepezza, which is the
brand name of teprotumumab in the U.S., using XeriJect
technology.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
January 10, 2024 08:38 ET (13:38 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
Amgen (NASDAQ:AMGN)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Amgen (NASDAQ:AMGN)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024
